The resolution designates May 5-11, 2024, as "Tardive Dyskinesia Awareness Week" to raise awareness about tardive dyskinesia (TD), a movement disorder that can occur in individuals treated with dopamine receptor blocking agents, such as antipsychotics and antiemetics. It highlights the prevalence of TD, affecting approximately 600,000 people in the U.S., with a significant portion remaining undiagnosed. The resolution emphasizes the importance of monitoring for TD symptoms and the availability of FDA-approved treatments, which can improve the quality of life for those affected.

The House of Representatives encourages the public and medical community to recognize the symptoms of TD and urges individuals experiencing uncontrollable movements to seek consultation with their healthcare providers. By designating this week, the resolution aims to foster greater understanding and support for those living with the condition, ultimately promoting better health outcomes through increased awareness and timely intervention.